Vor Biopharma (VOR) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Vor Biopharma

NasdaqGS•Healthcare•Biotechnology

$25.05+0.81(0.03%)Market closed

Market Cap

$1.25B

P/E

2.0x

Vor Biopharma Inc., a clinical-stage biopharmaceutical company, focuses on the development of a novel therapy in the treatment of autoimmune diseases. The company offers telitacicept, a novel fusion protein for the treatment of generalized myasthenia gravis, systemic lupus erythematosus, and rheumatoid arthritis, as well as Sjögren's disease and IgA nephrapathy. It has a license agreement with RemeGen Co., Ltd. for the exploitation, development, and commercialization of telitacicpet and related products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

How this company scores

WeakMetricSide Score: 38/100

Grade capped at D — Negative equity — the balance sheet is insolvent. Strongest: Growth (15/25); weakest: Cash & Earnings Quality (2/25).

Profitability6/25

Growth15/25

Balance Sheet & Red Flags15/25

Cash & Earnings Quality2/25

Strengths

Rising earningsInterest easily coveredProfit converts from growthNet cash position

Grade capped at D

Negative equity — the balance sheet is insolvent.

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 2.0x5y range 2.0x – 2.0x

P/B · 27.1x5y range 13.1x – 48.5x

Currently above its 15-quarter median.

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

Free cash flow has been negative in 8 of the last 8 quarters — earnings are not translating to cash.

Price & Volume

Market Cap $1.25B

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $0
Q. Revenue: $0
TTM EBITDA: $-147.05M
TTM Op. Income: $-147.08M
Q. Op. Income: $-47.85M
TTM Net Income: $627.78M
Q. Net Income: $-62.81M
EPS: $-1.16
Shares Out.: $54.30M

$0 in TTM revenue was flat at zero YoY, reaching $0 last quarter. TTM EBITDA of $-147.05M and TTM operating income of $-147.08M show growth is flowing through to the bottom line. TTM net income of $627.78M means revenue is converting into profit.

Margins

Gross, EBITDA, operating, and net margin trends

EBITDA Margin: N/A
Op. Margin: -4785300000.0%
Net Margin: -6281000000.0%

Op. margin of -4785300000.0% is up 22643100000.0% YoY — cost efficiency is improving. Net margin at -6281000000.0% Over the past year, operating margin is up 83% — a weakening trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: 2.0x
P/S Ratio: N/A
P/B Ratio: N/A

At 2.0x P/E, the stock trades below typical market levels. P/S of 0.0x and P/B of 0.0x provide additional context. Use the growth and margin sections to judge whether the multiple is justified.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $481.05M
Cash: $107.86M
Long-Term Debt: N/A
Book Value: $-200.20M
D/E Ratio: N/A
Debt/EBITDA: N/A

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $-25.38M
TTM Free Cash Flow: $-140.81M
FCF Margin: N/A
FCF / Net Income: -0.2

TTM FCF of $-140.81M on $-25.38M in operating cash flow. The FCF / Net Income ratio of -0.2x means the business consumes cash — it is not yet self-funding. Over the past year, free cash flow is down 23% — an improving trend.